---
title: Download the MASH case study
description: We discuss how the PXB-mouse was used to test elafibranor, a MASH drug candidate that failed to meet its primary clinical endpoint in Phase III trials.
image: https://www.phoenixbio.com/hubfs/PhoenixBio_Design_Social%20media%20image_AAV%20case%20study%20LinkedIn%20banner%202_V2_4Oct21%20(1).png
---

# Case study

# Download the case study: Advancing MASH therapeutics with a clinically relevant and translational human liver fibrosis animal model

![cover_UUGNAB94S](https://www.phoenixbio.com/hs-fs/hubfs/cover_UUGNAB94S.png?width=400&height=500&name=cover_UUGNAB94S.png)

Cases of the chronic liver condition, MAFLD, and its progressive form, MASH, are on the increase, yet there are currently no approved treatments for these conditions. 

A key barrier to pharmaceutical development is the poor translation of pre-clinical models to the human environment, with drug candidates failing to reach clinical endpoint at trial stages.

In this case study, we discuss how **the PXB-mouse® model was used to retrospectively test ****elafibranor, a potential MASH drug candidate that failed to meet its primary clinical ****endpoint in Phase III trials. **

**Simply fill out the form to get your copy.**

## Download the case study